As MESNA Stada is only used in combination with oxazaphosphorines (ifosfamide, cyclophosphamide or trofosfamide) for uroprotection in cytostatic therapy, criteria of such cytostatic therapy apply for use in pregnancy and lactation. Animal experiments have shown no evidence of embryotoxic or teratogenic effects of MESNA Stada.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
